Likely Sales Slump Puts (Still More) Heat On Amgen’s Denosumab To Win
Analyst questions whether the bone drug’s efficacy can beat Zometa’s by the necessary 15 percent.
Analyst questions whether the bone drug’s efficacy can beat Zometa’s by the necessary 15 percent.